NCT04663347 2026-03-03
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
Clinical Trials
13 trialsNCT03407144 2026-02-19
MK-3475-667
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT06230224 2026-02-06
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT02964013 2025-10-14
KEYVIBE-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01450761 2020-07-08
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Bristol-Myers Squibb
Phase 3 Completed
NCT00537511 2019-11-19
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
Celgene
Phase 1/2 Terminated
NCT00776802 2013-06-25
GCS-100LE
La Jolla Pharmaceutical Company
Phase 1/2 Withdrawn
NCT00621361 2012-12-17
Phase I Safety and Tolerability Study of Cediranib (RECENTINâ„¢, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
AstraZeneca
Phase 1 Completed
NCT01563601 2012-08-15
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Withdrawn
NCT00191139 2010-02-17
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Completed